相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
Saori Mishima et al.
ESMO OPEN (2018)
Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity
Pantelis Clewemar Antonodimitrakis et al.
NEUROENDOCRINOLOGY (2016)
The matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progression
Yu-Ting Huang et al.
ONCOTARGET (2016)
Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors
Daniela Mueller et al.
BMC CANCER (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours
Lisa-Marie Dilz et al.
EUROPEAN JOURNAL OF CANCER (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms - Predictive and Prognostic Markers for Treatment Stratification
Sebastian Krug et al.
PLOS ONE (2015)
Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer
Milind Javle et al.
CLINICAL CANCER RESEARCH (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Nicolo Rigamonti et al.
CELL REPORTS (2014)
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Jean-Yves Scoazec
NEUROENDOCRINOLOGY (2013)
Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients
Daniela Speisky et al.
CLINICAL CANCER RESEARCH (2012)
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
Anna Koumarianou et al.
ENDOCRINE-RELATED CANCER (2012)
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Elizabeth Allen et al.
CLINICAL CANCER RESEARCH (2011)
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Ben Lawrence et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ramucirumab (IMC-1121B): a novel attack on angiogenesis
Jennifer L. Spratlin et al.
FUTURE ONCOLOGY (2010)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
T. R. Halfdanarson et al.
ANNALS OF ONCOLOGY (2008)
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice
Sean P. Dineen et al.
CANCER RESEARCH (2008)
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Ulrich-Frank Pape et al.
ENDOCRINE-RELATED CANCER (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Sample size tables for exact single-stage phase II designs
RP A'Hern
STATISTICS IN MEDICINE (2001)
分享论文
